Click for next page ( 17

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 16
Appendix A Statement of Task An ad hoc committee will plan and conduct a public workshop that focuses on the manufacturing process and specifically on the development of "manufacturing platforms"—repeatable components of manufacturing that aim to reduce both development time and risk of vaccines and therapeutic proteins (e.g., monoclonal antibodies) targeted at specific agents within a few months after these agents are identified. This is important because a major component of the U.S. Department of Defense (DoD)/Transformational Medical Technologies Initiative (TMTI) efforts in biodefense is to develop vaccines and therapeutic proteins (e.g., monoclonal antibodies) targeted at specific agents within a few months after agents are identified. The workshop will feature invited presentations and discussions on various topics addressing integrated platforms to produce safe and efficacious surrogate countermeasures in contexts that are expected to mimic those of future threat agents and that could shorten the regulatory approval process. The agenda will include manufacturing-related characteristics of monoclonal antibodies and vaccines that confer safety and efficacy, attempting to highlight the most important critical quality attributes (CQAs) that stem from these characteristics and discussion of the extent to which these CQAs could form a basis for assuring production of safe and efficacious vaccines against novel agents, facilitating rapid approval of DoD countermeasure products by the FDA. It will also include the impact of the identified CQAs on the development/planning of manufacturing platforms and integration across multiple platforms, asking what should be considered in the development of manufacturing platforms to maximize the potential for consistency between existing and new monoclonal antibodies and vaccines. Additional discussion will center on whether there are characteristics of diseases or vaccines that will more readily lead to consistency between surrogate and new vaccines. 16